(ISRA) Israel - Overview
Etf: Technology, Pharmaceuticals, Defense, Financials, Energy
Dividends
| Dividend Yield | 1.44% |
| Yield on Cost 5y | 1.94% |
| Yield CAGR 5y | 8.76% |
| Payout Consistency | 78.9% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 20.0% |
| Relative Tail Risk | 4.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.40 |
| Alpha | 23.64 |
| Character TTM | |
|---|---|
| Beta | 0.875 |
| Beta Downside | 0.800 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.11% |
| CAGR/Max DD | 0.76 |
Description: ISRA Israel December 30, 2025
The VanEck Israel ETF (NYSE ARCA: ISRA) is a non-diversified fund that commits at least 80% of its net assets to the securities that compose its benchmark index, which is defined by MV Index Solutions GmbH as publicly traded Israeli companies (including depositary receipts). The fund’s objective is to track the performance of this Israel-focused equity index.
Key contextual drivers: (1) Israel’s equity market is heavily weighted toward technology and cybersecurity, sectors that together account for roughly 45% of the index’s market-cap weighting as of Q3 2024. (2) Recent macro data show Israel’s GDP growth at an annualized 3.2% YoY, outpacing many peers in the region, supporting corporate earnings growth. (3) The ETF’s top ten holdings represent about 55% of assets, indicating concentration risk that investors should monitor alongside the country-specific political risk profile.
For a deeper, data-rich assessment of ISRA’s risk-adjusted performance, consider reviewing the analytics available on ValueRay.
What is the price of ISRA shares?
Over the past week, the price has changed by +0.00%, over one month by +1.82%, over three months by +14.19% and over the past year by +38.81%.
Is ISRA a buy, sell or hold?
What are the forecasts/targets for the ISRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 70.2 | 11.6% |
ISRA Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 133.6m USD (133.6m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 133.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 133.6m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.14% (E(133.6m)/V(133.6m) * Re(9.14%) + (debt-free company))
Discount Rate = 9.14% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)